SLS
SELLAS Life Sciences Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.49
+5.11%Sep 25, 2026, 17:00 UTC
SELLAS Life Sciences presented preclinical data showing SLS009 (tambiciclib) activity in patient-derived organoid models of pancreatic ductal adenocarcinoma at the AACR Conference on Pancreatic Cancer in San Diego on September 25, 2026.
Source:Aug 27, 2026, 17:13 UTC
SELLAS Life Sciences Group Inc. stock surged on Thursday, with a year-to-date gain of about 300%.
Source:Aug 24, 2026, 14:06 UTC
Sellas Life Sciences shares fell 7.66% to $14.28 on August 24, 2026, after a German media report speculated that the REGAL Phase 3 trial may have reached the 80th event needed for final analysis, but the company has not officially confirmed this, leaving retail investors skeptical.
Source:Aug 18, 2026, 04:35 UTC
3D Medicines announced that the arbitration award in its favor against SELLAS Life Sciences Group has been fully executed, with SELLAS ordered to pay approximately 7.983 million yuan in costs, which has been received in full.
Source:Aug 17, 2026, 05:17 UTC
Goldman Sachs increased its stake in Capricor Therapeutics by 73% to 1.58 million shares valued at $38 million, and disclosed holdings in Sellas Life Sciences and ImmunityBio totaling nearly $75 million.
Source:Aug 11, 2026, 20:05 UTC
SELLAS Life Sciences Group reported its financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Source:Jun 26, 2026, 16:30 UTC
Sellas Life Sciences board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.
Source: